Johnson & Johnson (JNJ)
| Market Cap | 351.45B |
| Revenue (ttm) | 81.80B |
| Net Income (ttm) | 38.48B |
| Shares Out | 2.41B |
| EPS (ttm) | 15.09 |
| PE Ratio | 9.68 |
| Forward PE | 13.63 |
| Dividend | $4.96 (3.40%) |
| Ex-Dividend Date | May 20, 2024 |
| Volume | 3,715,016 |
| Open | 146.43 |
| Previous Close | 146.44 |
| Day's Range | 145.74 - 147.15 |
| 52-Week Range | 143.13 - 175.97 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 175.17 (+19.96%) |
| Earnings Date | Jul 17, 2024 |
About JNJ
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lu... [Read more]
Financial Performance
In 2023, JNJ's revenue was $85.16 billion, an increase of 6.46% compared to the previous year's $79.99 billion. Earnings were $35.15 billion, an increase of 95.94%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $175.17, which is an increase of 19.96% from the latest price.
News
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN,...
Cancer victims lose bid to block proposed J&J talc bankruptcy
A federal judge on Friday rejected a bid by a group of cancer victims to block Johnson & Johnson from pursuing a proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's ...
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADL a) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, an...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash ...
Lawyers for Johnson & Johnson's Ovarian Cancer Victims React to SCOTUS Decision in Purdue
WASHINGTON--(BUSINESS WIRE)--The U.S. Supreme Court has denied a $7 billion Purdue Pharmaceuticals bankruptcy plan which would have given the Sackler family, which founded the company, immunity from a...
Johnson & Johnson Completes Acquisition of Proteologix, Inc.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has successfully completed the acquisition of Proteologix, Inc., a privately-held biotechnology company focu...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
Submission is supported by 48-week results from the Phase 3 GALAXI and GRAVITI programs TREMFYA® is the only IL-23 inhibitor to demonstrate strong endoscopic outcomes with subcutaneous (SC) induction,...
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme
TRENTON, N.J.--(BUSINESS WIRE)--Some of the nation's largest law firms recognized for their committed and successful representation of individuals harmed by dangerous products have announced unified o...
5 Cheap Stocks Buying Back Shares at Reasonable Prices
Buybacks are in fashion. But at today's valuations, companies could be paying up for their own stock—and that's never a good idea, whether you're a CEO or a retail investor.
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
TREMFYA® Phase 3 Crohn's disease study achieves all primary and secondary endpoints SPRING HOUSE, Pa. , June 20, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive topline res...
J&J hit with new class action over talc seeking medical monitoring for cancer
Johnson & Johnson is facing a new proposed class action seeking damages and medical monitoring on behalf of women who have been diagnosed with cancer, or might develop it in the future, allegedly as a...
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-tim...
Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products
TRENTON, N.J.--(BUSINESS WIRE)--Plaintiffs who are at increased risk of ovarian cancer due to long-term use of Johnson & Johnson's Baby Powder have filed a class action lawsuit in New Jersey federal c...
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression...
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 study MADRID , June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) an...
Talc Plaintiffs File Motion for Temporary Restraining Order to Limit Johnson & Johnson's Use of Bankruptcy Strategy
TRENTON, N.J.--(BUSINESS WIRE)--A group of ovarian cancer victims has filed a motion in federal court seeking to halt Johnson & Johnson (NYSE:JNJ) and its subsidiaries from pursuing a new bankruptcy f...
Cancer victims ask court to block J&J talc bankruptcy
A group of cancer victims asked a federal judge to block Johnson & Johnson's proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products ...
Johnson & Johnson to pay $700 million settlement over talc products linked to cancer
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly ...
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, even when markets are at all-time highs, many investors turn to dividend-yielding stocks. These are often companies that have high free cash ...
With A Similar Revenue Base Is Johnson & Johnson A Better Pick Despite The 30% Fall In Tesla Stock This Year?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over the auto giant Tesla (NASDAQ: TSLA). The decision to invest often comes down to finding the...
Johnson & Johnson reaches $700 million talc settlement with US states
Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other products that contained talc.
J&J-backed Rapport Therapeutics valued at $636.8 mln after shares rise 6% in debut
Shares of Rapport Therapeutics , backed by Johnson & Johnson's venture capital arm, rose nearly 6% in their market debut on Friday, valuing the early stage therapy developer at $636.8 million.
J&J-backed Rapport Therapeutics raises $136 mln in US IPO
Rapport Therapeutics said on Thursday that it has raised $136 million in its initial public offering in the United States at a valuation of about $601.4 million.
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaq...
Cramer's Mad Dash: Johnson & Johnson
CNBC's Jim Cramer delivers his daily Mad Dash.